# Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) assessment tool 

Complete this baseline assessment prior to starting treatment. It is recommended that ICANS assessments are completed at least twice daily. Increase frequency as clinically indicated.

ICANS grade is determined by the most severe event (immune effector cell-associated encephalopathy (ICE) score, level of consciousness, seizure, motor findings, raised intracranial pressure/cerebral oedema) not attributable to any other cause; for example, a patient with an ICE score of 3 who has a generalised seizure is classified as Grade 3 ICANS.

| Hospital ID: |  |  |
| :--- | :--- | :--- |
| Surname: |  |  |
| Given names: | Sex: | AMO: |
| Date of birth: |  |  |

## Pronouns:

Preferred names:
\(\left.$$
\begin{array}{|lll}\hline \text { Immune effector cell-associated encephalopathy (ICE) assessment } & \\
\hline \text { If the patient's ICE score is } 9 \text { or below, notify physician immediately. } & \\
\hline \text { Orientation } & \text { Orientation to year, month, city, hospital } & 4 \text { points } \\
\hline \text { Naming } & \text { Ability to name 3 objects (e.g. point to clock, pen, button) } & 3 \text { points } \\
\hline \begin{array}{l}\text { Following } \\
\text { commands }\end{array}
$$ \& \begin{array}{l}Ability to follow simple commands (e.g. "Show me 2 fingers" <br>

\hline Writing\end{array} \& Ability to write a simple sentence (e.g. "The emu is an Australian animal")\end{array}\right] 1\) point | Attention | Ability to count backwards from 100 by 10 |
| :--- | :--- |

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) assessment

| Neurotoxicity <br> Domain | Grade1 | Grade 2 | Grade 3 | Grade 4 |
| :--- | :--- | :--- | :--- | :--- |
| ICE assessment <br> score | $7-9$ | $3-6$ | $0-2$ | 0 (patient is unarousable and unable <br> to perform ICE) |
| Depressed <br> level of <br> consciousness | Awakens <br> spontaneously | Awakens <br> to voice | Awakens only to tactile stimulus | Patient is unarousable or requires <br> vigorous or repetitive tactile stimuli <br> to arouse. Stupor or coma |
| Seizure | N/A | N/A | Any clinical seizure focal or <br> generalized that resolves rapidly <br> or nonconvulsive seizures on EEG <br> that resolve with intervention | Life-threatening prolonged seizure (>5 min); <br> without return to baseline in between |
| Motor findings | N/A | N/A | N/A | Deep focal motor weakness such <br> as hemiparesis or paraparesis |
| Elevated <br> cerebral <br> oedema | N/A | N/A | Focal/local oedema on <br> neuroimaging | Diffuse cerebral oedema on neuroimaging; <br> Decerebrate or decorticate posturing; or Cranial <br> nerve VI palsy; or Papilledema; or Cushing's <br> triad (irregular/decreased respirations, <br> bradycardia and systolic hypertension) |

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) assessment chart
Complete this baseline assessment prior to starting treatment. It is recommended that ICANS assessments are completed at least twice daily. Increase frequency as clinically indicated.

If the patient's ICE score is 9 or below, notify physician immediately.


ICANS grading

## Date

Time
ICANS Grade 1-4
Assessors signature

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) assessment chart
Complete this baseline assessment prior to starting treatment. It is recommended that ICANS assessments are completed at least twice daily. Increase frequency as clinically indicated.

If the patient's ICE score is 9 or below, notify physician immediately.


| ICANS grading |
| :--- |
| Date |
| Time |
| ICANS Grade 1-4 |$\quad$

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) assessment chart
Complete this baseline assessment prior to starting treatment. It is recommended that ICANS assessments are completed at least twice daily. Increase frequency as clinically indicated.
If the patient's ICE score is 9 or below, notify physician immediately.


| ICANS grading |
| :--- |
| Date |
| Time |

E: feedback@eviq.org.au
W: eviq.org.au
© Cancer Institute NSW. Version 2. Last reviewed November 2023. This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the contents at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury, or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. See www.eviq.org.au for our full disclaimer and any updates.

